Developing life-changing, innovative therapies for diseases with unmet needs Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. Intranasal Drug Delivery, Migraine, Parkinson's Disease, CNS Therapeutics, and Autism

238 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Toward the next generation of gene therapy. Spur Therapeutics (formerly Freeline Therapeutics) is a clinical-stage biotechnology company focused on developing life-changing therapies for debilitating chronic conditions. By optimizing every component of our product candidates, we are improving genetic expression and targeted delivery to realize outsized clinical results. Building on the successes of our two potential first-in-class therapies for Gaucher disease and adrenomyeloneuropathy (AMN), we’re moving from rare diseases toward more widespread conditions, including forms of Parkinson’s and dementia, and even certain cardiovascular diseases. Expanding our impact, and pushing forward to new frontiers of genetic medicine. Toward life-changing therapies, and brighter …

181 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Clinical stage biotech company developing a new modality of oral biologics that act on cells in the small intestine. Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAXTM, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people …

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

459 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe respiratory diseases Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing

169 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. biotechnology, research, T cell, biologics, and science

211 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the full potential of cell therapies for patients around the world SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under …

186 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: - Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. - EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in …

199 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Using mesenchymal stem cells to produce therapeutically meaningful extracellular vesicles. We are a recently incorporated limited company, spun out from the University of York from the Genever lab (www.geneverlab.info), which has over 20 years of experience in cell biology and regenerative medicine. We focus on musculoskeletal regeneration using mesenchymal stem cells (MSCs), with a view to translate our body of work into cutting edge therapeutics. Our current focal point is the field of extracellular vesicles (EVs), which have recently gained substantial traction as a next-generation therapeutic modality. We believe that current approaches have room for improvement in terms of consistency …

93 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Pioneering Next-Generation Stroke Treatments 👉Funding round is still open: https://capitalcell.com/campaign/freeox/ FreeOx Biotech: Advancing Stroke Care through Innovation and Precision Medicine FreeOx Biotech is a pioneering late-stage clinical biotechnology company dedicated to transforming acute ischemic stroke (AIS) management. Our mission is to improve outcomes for stroke patients through the discovery and development of Cerebrovascular Protective Therapeutics. Our lead asset, Ox-01, is a Phase 3-ready investigational drug with breakthrough potential as an emergency adjunct therapy to Mechanical Thrombectomy. Selected by the prestigious StrokeNet Thrombectomy Endovascular Platform (STEP) program, funded by the National Institute of Neurological Disorders and Stroke (NINDS), Ox-01 represents a …

63 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

evaxion.ai Evaxion A/S is a pioneering TechBio company based upon its AI platform, AI-ImmunologyTM. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-ImmunologyTM, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-ImmunologyTM platform and vaccine …

60 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology

Alternative to Animal Testing for Drug Development Cherry Biotech is a biomedical technology (Organ on Chip) company that develops instruments for drug discovery and personalised medicine. Its mission is to replace animal testing by reconstructing human tissue (Organoids) in vitro for drug testing. Cherry Biotech's CUBIX platform enables pharmaceutical, biotech companies and healthcare providers to recreate immunocompetent human vascularized organ models and tumor microenvironments for better evaluation of their drug candidates. By enabling the reconstruction of human 3D models that mimic human physiology and pathophysiology over several weeks, Cherry Biotech's proprietary CUBIX technology is the only solution that can convert …

141 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

less complexity. more biology. At Chromodynamics, we are on a mission to deliver instruments that eliminate guesswork from drug development and prescription. Our unique technology allows for an enormous improvement in speed, efficacy, and cost with which exciting new treatments like immunotherapy are developed. We have been recognised as one of the most promising startups in the Eindhoven Brainport region and are expanding our team to ramp up our product development. Imaging systems, Multispectral imaging, Real-time analysis, Chemical imaging, Spectroscopy, Scientific instruments, Contract research, and Data analysis

931 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Valora Therapeutics is a privately held biotech, co-founded with Carolyn Bertozzi, developing multispecific antibodies and T cell engagers that break the glyco-immune checkpoint. Our proprietary AbLecTM and T-LecTM platforms combine precise tumor targeting with localized glyco-immune checkpoint disruption to generate therapeutics with superior anticancer activity without the requirement for delivering toxic payloads. Valora's discovery engine was built on a $30M Seed Round led by Avalon BioVentures.

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Restoring life after organ failure. eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant. Genome Engineering

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Platelet Secretome : a New Therapeutic Strategy Against Neurodegeneration InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

158 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

372 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We create ophthalmic therapeutic bio factories to sustainably treat major eye diseases. Eyevensys is a clinical stage, private, biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease. EyeCET stands for the eye ciliary muscle electro-transfection technology, which uses electroporation to deliver plasmids coding for therapeutic proteins in the eye. EyeCET is safe and non-viral, and it enables the ciliary muscle cells to sustainably produce therapeutic proteins locally. Eyevensys believes its EyeCET technology can improve short and long-term therapeutic outcomes, greatly enhancing patient compliance and significantly …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has over 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s …

75 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health. Biochemistry, Immunology, Oncology, Regenerative Medicine, Cell therapies, and Proteins

121 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering drug discovery company exploiting cutting edge technologies to create best-in-class small molecule medicines C4XD is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‐leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD …

295 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Let's Build Better Cells Together At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQureTM gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping …

334 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing healthcare with exosomes focusing on gastrointestinal, liver and kidney regeneration EverZom is an exosome biotech company developing treatments for digestive tissue healing like Crohn's fistula and organ regeneration like the kidney and the liver. Founded in 2019, EverZom is positioned to become the leader of exosome therapeutics, the next wave of innovation for the biotech industry. Exosomes, small vesicles secreted by cells, are increasingly recognized as potent agents for intercellular communication and play a crucial role to treat a wide range of diseases. Winner of the European EIC Accelerator Program, EVerZom aims to be the upcoming pioneer in this …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Intracellular delivery and neuroprotection — two patented technologies from Institut Pasteur research. Neurophoenix is a preclinical-stage biotechnology company arising from academic research carried out at Institut Pasteur. It holds two complementary patented technologies. VHH_NPX is a single-domain antibody engineered to cross two barriers that stop most therapeutics: the blood–brain barrier, and then the plasma membrane of the neuron itself — releasing its cargo directly into the cytosol rather than leaving it trapped in the endosomal compartment. NVshort is a short neuroprotective and neuroregenerative peptide, derived from a rabies virus glycoprotein motif, which selectively inactivates the PTEN–MAST2 interaction and reactivates the …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: SaaS

Platform to transport and deliver nucleic acid to the central nervous system in a repetable and non-invasive way Harmonix, a breakthrough technology to deliver molecules, including viral and non-viral gene therapy, in a targeted and non-invasive manner, in the central nervous system. We develop innovative microbubbles who are able to encapsulate molecules and deliver them in a non invasive way in the brain. Biotech, Central Nervous System, Gene delivery, Non-viral and viral gene delivery, Research, and Glioblastoma

104 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Tailor-made recombinant proteins CytobodX is a CRO company based in Marseille, France. At CytobodX, we produce, purify and characterize soluble and membrane proteins using state-of-the-art technologies to meet the specific needs of your research. The originality of CytobodX is to be able to rapidly produce native membrane proteins by using an innovative technology. Membrane proteins are directly expressed and embedded on the surface of purified Extracellular Vesicles (EVs) and ready for downstream applications : Interaction or functional studies, structural characterization or antibody/nanobody generation. This technology allows CytobodX to guarantee optimal quality and stability of the proteins produced and marketed. contact: …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeting protein degradation at the point of synthesis Enodia Therapeutics is a French biotech company building a proprietary small-molecule platform that selectively modulates the SEC61 translocon, a central control point of the protein secretion pathway. By intervening at the point of synthesis, Enodia redirects disease-driving secreted and transmembrane proteins toward early degradation, before they mature or exert pathological effects, while preserving normal cellular function. Leveraging a deep, well-characterized chemical space of SEC61 inhibitors, together with proteomics and machine-learning–guided drug design, Enodia enables highly selective, upstream intervention across multiple indications, starting with inflammatory and autoimmune diseases.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AveXis is now Novartis Gene Therapies Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA). Follow us on LinkedIn: https://www.linkedin.com/company/novartis-gene-therapies/ How to reach us: Novartis Gene Therapies 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: gtx.communications@novartis.com Office Phone: 847.572.8280 Toll-free Phone: 844.428.3947 Gene Therapy, Synthetic Biology, and Spinal Muscular Atrophy

221 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

SITERA is developing new therapies to tackle neurodegenerative diseases and meet the urgent needs of all patients SITERA Pharmaceuticals is a preclinical-stage biotech developing small molecule therapeutics that target Mitochondria-Associated Membranes (MAMs), a critical hub for neuronal signaling and metabolism. Our mission: deliver innovative therapies for patients with rare and prevalent neurodegenerative diseases who have run out of options. Leveraging a proprietary platform combining cutting-edge chemistry and biology, we design potent, selective, and safe CNS therapeutics, addressing some of the most challenging unmet needs in neurology. Biotechnology, Neurodegenerative diseases, and Central Nervous System

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Xbrane is a leading science based biosimilar developer of cost effective medicines with high unmet medical need Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. We enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. Xbrane posses world leading expertise in developing true generics for injectable controlled release drugs and proprietary high-yield protein expression technology. Complex generics, Protein expression, Biosimilars, Controlled release, Strain development, and Formulation

112 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The CanVas platform is focused on developing novel cell therapies. The CanVas platform is spearheading the development of investigational allogeneic candidates for neurologic, rare and other serious diseases. Our world class team are dedicated to advancing a wave of investigational allogeneic products through excellence in translational research, clinical development and cell manufacturing. We are developing a pipeline of off-the-shelf cell therapies based on the pioneering Can-Vas platform. This could allow for the delivery of cell therapies to patients faster when they need it most and at greater scale. Our mission is to have a transformative impact on patients’ lives by …

245 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

HA is foundamental in ophthalmology. Noxelis is engineering what comes next. Noxelis is a French ophthalmic medical device company dedicated in developing next-generation treatments, including polymers and hyaluronic acid as a cornerstone. Through its technological platform, Noxelis proposes different formulations aimed at improving medical practice and provides ophthalmologists with first-in-class therapies to treat ocular surface diseases. Noxelis was founded by a passionate and determined team to bring innovative technologies to market with one focus: Bring patients' ocular comfort to the next level.

58 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Developing Bioprinted Tissue Therapeutics to transform how we treat some of the most elusive diseases. Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders. bioprinting, regenerative medicine, therapeutic development, …

64 similar entities Type: Startup Activities: deeptech biotech Technologies: 3D Printing New Materials Synthetic Biology

We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating a New Class of Medicines to Drug the Undruggable InFocus Therapeutics is an AI-driven drug discovery company pioneering best-in-class RNA-targeting molecular glues to unlock new chemical space for transcriptional modulation and address diseases with high unmet need. Powered by a scalable, tech-enabled discovery engine, we are advancing a diversified pipeline across oncology and neuromuscular indications, with multiple programs progressing toward preclinical proof-of-concept. With a world-class founding team, strong IP, and multi-billion-dollar market potential across indications, InFocus is positioned to deliver transformative patient outcomes and sustainable value creation.

82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building the Future of Precision Medicines through V-Body, RNA and In Vivo Cell Engineering Platforms. At Valerio Therapeutics, we are pioneering a new generation of precision therapies to tackle complex and underserved diseases. Our proprietary V-Body platform is based on two fully synthetic single-domain antibody (sdAb) libraries, derived from a human VH and a fully humanized VHH. Engineered for optimal performance, this ultra-small sdAb platform (~15 kDa) surpasses the limitations of current treatments by enabling deep tissue penetration and highly precise therapeutic delivery, ensuring superior efficacy and target engagement. Our approach integrates innovative target identification using advanced predictive models, antibody …

227 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases neurodegeneration, RNA therapeutics, physiological upregulation, post-transcriptional upregulation, mRNA, ASO, and SINEUP

209 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Harnessing natural messengers for innovative therapeutics Ciloa is a pioneer in the bioengineering of extracellular vesicles to develop new generations of therapeutics and preventive solutions to improve patients' lives. Ciloa bioengineers sEV proteins, to turn them into natural messengers with huge medical potential. Our bioengineered sEVs can be used as therapeutic solutions in a number of medical fields, including oncology, metabolic diseases, rare diseases and age-related illnesses. Mastering sEV engineering, we have produced sEVs containing a stable, highly multimerised and functional adiponectin (APN), a hormone well known as our “Guardian Angel” for its insulin-sensitizing, anti-inflammatory and anti-oxidative stress properties. Ciloa’s …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣 Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of …

283 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

"Designs the immunotherapy of tomorrow" At Allogenica, we are transforming cell therapies for a healthier tomorrow. Our mission is to disrupt the treatment landscape for cancer, rare diseases, and autoimmune disorders. We're developing a breakthrough cell therapy platform with the potential to: • Replace transplants: Providing less invasive, accessible alternatives for thousands of patients who currently have limited treatment options. • Expand access for all: With predictable safety and efficacy, we aim to make cell therapies available to a a broader patient population. • Dramatically reduce costs: By streamlining production, we aim to significantly lower the cost of cell therapies, …

178 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Reducing the gap between Lab and Clinical Trials with Physiological and Pathological Non-Animal Models Unique R&D platform of donor-derived real human adipose tissue ex vivo models for pharmaceutical drug development (obesity, chronic metabolic diseases), dermo-cosmetic, nutraceutical, aesthetic and reconstructive surgery research. ExAdEx-Innov owns exclusive worldwide rights to ExAdEx patented breakthrough technology to develop preclinical models derived from human adipose tissue obtained from patients. These models maintain their native 3D structure, stem cells, functionality, and vascularization over the long term in culture, providing a faithful representation of clinical conditions. They enable the pharmaceutical industry to generate reliable human data in the …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

565 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Overcoming Challenges, Innovating Hope An innovative molecule to reshape the future of the brain Glyx Therapeutics is dedicated to transforming the lives of patients by pioneering innovative treatments for neurodegenerative disorders with urgent, unmet medical needs. Our work focuses on tackling orphan tauopathies and Alzheimer’s disease, bringing hope and solutions to those facing these challenging conditions.

174 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Unlocking in vivo cell therapy with the next generation of gene editing technology Brink Therapeutics is developing next-generation recombinases — ultra-precise and efficient enzymes that surpass CRISPR-Cas9. We aim to revolutionize Cell and Gene therapies, enabling large-scale production to treat cancer, genetic disorders, and other diseases.

105 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Enhancing the transport of therapeutic and imaging agents using versatile and flexible targeting technologies VECT-HORUS, Breaking barriers Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumours. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (first and foremost the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Vect-Horus endorces a mixed business model, based …

61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovative Vaccines for a Healthier World ExpreS2ion Biotechnologies is a clinical-stage DK based biotech company specialised in the development of new vaccines and immunotherapy products. The company has a clinical Phase III-proven discovery platform built around a proprietary recombinant expression system, ExpreS2 TM, developed especially for fast and efficient development and production of complex proteins required for innovative new vaccines, immunotherapy and diagnostics. The system also includes functionally modified glycosylation variants. For the clinical Phase I-stage therapeutic breast cancer vaccine, ES2B-C001, the Company employs a novel plug-&-play capsid virus-like particle (cVLP) platform, that offers competitive advantages in terms of long-term …

63 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

390 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We believe that everyone - irrespective of who they are or where they live - deserve medications that work We believe that everyone - irrespective of who they are or where they live - deserve medications that work

310 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our lead programme is in the area of rare genetic kidney disease.

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies

296 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Reinventing Cancer Immunotherapy Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea …

188 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Exosome-based therapeutics Exogenus Therapeutics is an innovative biotech start-up dedicated to early stage development of therapeutic tools. Using an exosome-based platform technology, Exogenus is developing biologic products for diseases with high unmet needs, such as inflammatory and autoimmune diseases. Driven by the urgency imposed by the COVID-19 pandemic, the company is currently developing solutions for the treatment of severe lung inflammation, a condition with limited treatment options and a common cause of death following SARS‐CoV‐2 infection. Contact us at team@exogenus-t.com Biotechnology, Regenerative Medicine, Stem cells, exosomes, cell biology, and therapies

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

296 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease

257 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Treating Neurodegenerative Disease by Restoring Autophagy At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families. biotechnology, biopharmaceuticals, rare disease, neurodegeneration, longevity, drug discovery, and drug development

428 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Zerion Pharma is a pharmaceutical company transforming the landscape for formulation of poorly soluble drugs Zerion is a pharmaceutical company transforming the pharmaceutical landscape for formulation of poorly soluble drugs that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, we aim to develop new treatment options for patients across all small molecule therapy areas. We are focused on improving existing drug products by building an internal pipeline, while partnering with originators to enable their early stage drug molecules, striving to improve the lives of patients around the world. Pharmaceuticals, Formulation, and Drug delivery

184 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

435 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science for cure. NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden. Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy. Biopharmaceutical company, Immunotherapy, and Immuno-oncology

299 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bridging research and translation for a healthy future. ImmuneBridge is building a world where high quality cell therapies can be rapidly designed and easily manufactured at commercial scale and ultralow cost. Cell Therapy, Immunotherapy, CAR-NK, Natural Killer Cells, and Oncology

182 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Translation-X is a biotech company developing novel, targeted therapeutics for neurodevelopmental disorders. Translation-X is a spin-off project at the Biozentrum, University of Basel. We are developing novel pharmacological tools to reduce core symptoms of autism by targeting RNA translational machinery.

63 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Making tissue therapeutics possible to defeat serious disease Fluicell is transforming how we treat disease with one-of-a-kind tissue solutions for regenerative medicine and drug screening. With the groundbreaking Nexocyte platform, based on twenty years of disruptive and patent-protected R&D, we are creating new ways to target serious diseases using precision-engineered biological tissues. Our transplantable tissues have the potential to help patients living with uncurable tissue damage related to cardiac, pulmonary, metabolic, kidney and other diseases. Fluicell’s first ambitious goal is to develop transplantable tissues to cure type 1 diabetes, impacting the lives of millions of patients. Nexocyte-generated tissues also enable …

98 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A leading nationwide clinical research site network pursing life-changing therapies committed to better patient outcomes CenExel is a leading integrated, wholly owned, nationwide clinical research site network comprised of 18 Centers of Excellence in major metropolitan areas across the U. S. With 40+ years of experience, our Centers of Excellence deliver deep scientific expertise, premium data, operational efficiencies, and exceptional patient engagement to drive successful complex clinical trial outcomes. The world's most results-driven Pharma, Biotech, and Clinical Research Organizations trust our strategic approach and benefit from our collaboration and unified sites’ commitment to real world solutions. Rely on us to …

131 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Tackling the toughest cancers. We’re OxSonics, a pioneering clinical-stage medical device company committed to developing a ground-breaking platform technology to deliver anti-cancer drugs so they can act smarter, act faster and, above all, work better. Our SonoTran® Platform has been designed to actively enhance the delivery of oncology drugs into solid tumours. SonoTran® is drug agnostic and requires no drug reformulation enabling its use with both existing and novel therapies. We have our own development programs as well as collaborations with Pharmaceutical and biotech companies to work to bring smarter, faster and better therapies to as many patient groups as …

192 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building an integrated group of European pharmaceutical subcontractors Oxurion is a Euronext Brussels-listed holding company focused on building a next-generation European platform dedicated to clinical data, biometrics and AI-driven clinical research services. Through a targeted buy-and-build strategy, Oxurion aims to consolidate high-value CRO and clinical technology capabilities across Europe Platform Highlights - 72% controlling stake in (Axiodis CRO), a French specialist in clinical biometrics and data management - Proprietary Next-Gen eCRF & Data Management System: Exagis - 7,000+ patient files processed across 12+ countries - 20+ active academic, biotech and pharmaceutical partners Expertise spanning biometrics, data management, statistical analysis and …

55 similar entities Type: Startup Activities: biotech Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

582 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Transforming the way challenging diseases and conditions are treated. Noveome Biotherapeutics, Inc. is a clinical stage company focused on breakthrough therapies for the regenerative repair of inflamed or damaged tissues. The company, originally founded as Stemnion, Inc., is located at RIDC Park, in the Fox Chapel area of Pittsburgh. Noveome is passionate about growing its business in Allegheny County and helping the region to become a world leader in biotherapeutic research and development. Noveome Biotherapeutics, Inc. is a dynamic biopharmaceutical company with an innovative platform technology that represents a paradigm shift in drug development. Unlike most drugs that are single …

61 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our Vision We aim at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing. Our Mission AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs. Research, Innovation, Technology, In-vitro, 3D Cell Culture, Organ-on-Chip, Respiratory diseases, Drug Development, Drug Discovery, Preclinical Services, Safety, Efficacy, …

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering Antibody Innovations to Defeat Cancer At VERAXA Biotech (NASDAQ:VRXA), we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including antibody-drug conjugates (ADCs), bispecific T cell engagers (BiTAC TCEs), and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA Biotech was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technologies. Cancer Research, Drug Development, …

192 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. Our Phase 3 lead asset, EryDex, is the first product in development that leverages our proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. Red blood cells have several characteristics that make them a potentially effective vehicle …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

miRNA-enhanced Extracellular Vesicles Therapeutics ConvEyXO, founded in 2019 by veterans of pharma industry, builds a specialized technology platform to convey exosome-based therapeutics to the market. The company is developing is therapeutic portfolio in the field of fibrosis and chronic inflammatory disorders. The rapid development of the company is the result of collaborations with partners with a demonstrated track record in healthtech and biotech fields manufacturing, process development, upstream, downstream, extracellular vesicles, exosomes, therapeutics, cargo, Loading, 4D, and exosomes

444 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AgeX Therapeutics is focused on the development and commercialization of novel therapeutics targeting human aging. AgeX Therapeutics, Inc. (“AgeX”) is a biotechnology company focused on the emerging field of interventional gerontology. Its technology platform is built upon a modern understanding of the molecular basis of cellular immortality and regenerative biology. Leveraging technology licensed from parent company BioTime, Inc. as well as Geron Corporation, AgeX is leading the development of novel therapeutics targeting some of the largest market opportunities associated with an aging population.

62 similar entities Type: Startup Activities: deeptech biotech silvertech Technologies: Synthetic Biology

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions. VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need. By combining state-of-the-art technologies and novel and scientific concepts, VectorY’s mission is to bring innovative therapies to patients worldwide. Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Seeking to improve lives through the curative potential of gene therapy. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with …

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS

Unlock the potential of your drug with our expertise in Transdermal and complex Injectable product development Nemaura Pharma is a private specialist biotech company who have developed several advanced versatile skin drug delivery systems. Our technologies have been designed with clinical needs in mind and are all minimally invasive and very cost-effective. We are strategically positioned to work with global pharmaceutical companies, as well as new biotechnology companies, to successfully bring both new and old drugs to patients in superior delivery formulations and systems. Founded in 2005 Nemaura has its headquarters and laboratory facilities in the United Kingdom at the …

172 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. …

437 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology